Theragenics (Buford, Georgia) said that Congress recently enacted the Medicare, Medicaid and SCHIP Extension Act of 2007, extending the Medicare safeguards initially enacted by Congress in 2003 for brachytherapy seeds administered in the hospital outpatient setting. The new legislation includes an extension of the current reimbursement policies for brachytherapy seeds through June 30, 2008, ensuring that the Medicare program does not implement potentially restrictive caps on reimbursement during that period.

Theragenics serves the cancer treatment and surgical products markets.